Baseline Serum Cholesterol Levels Predict the Response of Patients with Advanced Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitor-Based Treatment [Corrigendum]

Baseline Serum Cholesterol Levels Predict the Response of Patients with Advanced Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitor-Based Treatment [Corrigendum]

Tong III J, Mao Y, Yang Z, et al. Cancer Manag Res. 2021;13:4041–4053. The authors have advised due to an error at the time of figure assembly, Figure 2D on page 4048 is incorrect. The correct Figure 2 is shown in Download Article:   The authors apologize for this error...

Full description

Bibliographic Details
Main Authors: Tong III J, Mao Y, Yang Z, Xu Q, Zheng Z, Zhang H, Wang J, Zhang S, Rong W, Zheng III L
Format: Article
Language:English
Published: Dove Medical Press 2022-05-01
Series:Cancer Management and Research
Online Access:https://www.dovepress.com/corrigendum-baseline-serum-cholesterol-levels-predict-the-response-of--peer-reviewed-fulltext-article-CMAR

Internet

https://www.dovepress.com/corrigendum-baseline-serum-cholesterol-levels-predict-the-response-of--peer-reviewed-fulltext-article-CMAR

Similar Items